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ABSTRACT
Background: Perimenstrual asthma (PMA) has been documented in 30% to 40% of asthmatic women; the
characteristics of PMA have also been well described. However, there have been few epidemiological investi-
gations of PMA in practice. In this study, we analyzed PMA based on a questionnaire survey carried out in Ja-
pan and compared the results with those of studies reported previously.
Methods: For 8 weeks from September through October 2004, a questionnaire survey was administered to
patients with bronchial asthma and their attending physicians. The questionnaire surveyed asthma control,
asthma-related emergencies and satisfaction in daily life. The attending physicians were questioned about pa-
tient profiles and medications. All female patients who were menstruating during the survey period and who
were known to have asthma exacerbation related to menstruation were allocated to the PMA group; those who
were not were allocated to the non-PMA group.
Results: The rate of PMA in female patients who were menstruating during the survey period was 11.3% in
this study. Characteristic features of the PMA group (n = 54) included more severe disease, worsened disease
control and more aggressive patient management, including increased oral corticosteroid use compared with
the non-PMA group. The rates of emergency episodes in the PMA group were higher than in the non-PMA
group. There was a significant increase in aspirin intolerant asthma (AIA, 25.5%) in the PMA group compared
with the non-PMA group (8.4%).
Conclusions: Attention should be paid to the lack of knowledge regarding PMA in patients with asthma in ac-
tual clinical settings. The low rate of PMA reported in this study may be due to the study method using self-
reports of PMA by patients without sufficient knowledge, and may not be an accurate representation of the ac-
tual incidence of the disease. The clinical similarity of PMA to AIA in this study may also provide a new insight
into the mechanism of PMA.
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INTRODUCTION
It is well known that some female patients with
asthma experience an exacerbation of asthma symp-
toms during the premenstrual or menstrual phase of
their cycle. This has been described using the term
menstrual or perimenstrual asthma (PMA). After
Frank’s first report on PMA in 1931,1 many studies fo-
cused on the relationship between menstruation and
asthmatic symptoms.2,3 In the 1980s, the characteri-
zation of PMA was well established, including peak
expiratory flow (PEF) abnormalities in addition to in-
creases in asthmatic symptoms during the perimen-
strual phase in PMA patients.4 Recent studies have
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highlighted the causes of PMA, such as the role of
hormones.5,6
Because bronchial asthma is one of the most com-
mon diseases, management of bronchial asthma, in-
cluding medical interviews, can play an important
role in actual clinical settings. During the medical in-
terview, it is very important for the physician to note
predictive factors of asthma exacerbation, such as
menstruation. However, there is likely to be a dis-
crepancy between studies of PMA and the perception
of PMA by physicians in practice and the relationship
between asthma exacerbation and menstruation may
not receive adequate attention. Although around 30%
to 40% of women with asthma report perimenstrual
worsening of symptoms,7-10 many physicians tend to
think that the rate of PMA is much lower. This is be-
cause both female patients and their physicians have
paid little attention to PMA.11 It is clear that adequate
information about PMA, including characteristic
symptoms, hyperresponsiveness and respiratory dys-
function,12-15 pathogenesis5,6 and therapy,12,16 are well
documented. However, there are few studies that
compare PMA patients with non-PMA patients using
a questionnaire survey, include all patients with
asthma, and are administered in an actual clinical set-
ting. Hence, we designed a study of PMA in actual
practice. The prevalence of the conception that PMA
is not widely accepted in an actual clinical setting can
improve the management of asthma.
A questionnaire survey was administered by the
Niigata Asthma Treatment Study Group; the survey
took problems regarding asthma management into
consideration. The subjects in this survey were adult
patients with bronchial asthma who visited medical
institutions in Niigata Prefecture, starting in 1998.
The attending physicians of these patients were in-
cluded in the survey. Based on these surveys, we
have reported the clinical characteristics of adult
bronchial asthma patients,17 the characteristics of eld-
erly bronchial asthma18 and near fatal asthma,19 the
relationship between smoking and gender in asthma
patients20 and changes in asthma management.21,22
At the beginning of this survey (1998), there were no
questions about the relationship between asthma
symptoms and the menstrual phase: these questions
were added in 2004 for the reasons mentioned above.
In this paper, the analysis was based on the results
obtained from surveys conducted from 2004 onwards
in order to examine PMA in an actual clinical setting.
METHODS
The questionnaire used in this study was adminis-
tered in Niigata Prefecture, Japan, under the Ethical
Principles for Medical Research Involving Human
Subjects, Declaration of Helsinki. The institutions in-
volved were 28 large hospitals (200 beds or more), 15
small hospitals (<200 beds) and 35 clinics (no beds).
Three thousand six hundred and fifty questionnaires
were prepared and 2,865 were answered (response
rate: 78.5%). The contents of the questionnaire are
shown in Table 1 (originally in Japanese). The ques-
tionnaire was carried out over 2 months from Septem-
ber to October 2004. Subjects were adult patients
(aged 16 years and over) with bronchial asthma who
regularly visited the participating institutes for
asthma management (typically once or twice per
month). The recruited patients were asked to com-
plete the questionnaire by themselves. Therefore, the
understanding of technical terms such as “attack” or
“unconsciousness” in the questionnaire (Table 1) de-
pended upon the individual patients.
For an evaluation of asthma control, patients were
asked about their mean expiratory peak flow value
(PEFV) and the incidence of asthma attacks during
the 2 weeks prior to answering the questionnaire.
During the year prior to the questionnaire, the pa-
tients were also asked about their asthma by choos-
ing one of the following three answers: “few attacks,”
“seasonal attacks,” and “frequent attacks.” They were
also asked about asthma-related work or school ab-
sences. The questionnaires asked about asthma-
related symptoms in the 2 weeks prior to the ques-
tionnaire, including cough and sputum in the morn-
ing and at night, and sleep disturbances. The ques-
tionnaire also inquired about asthma-related emer-
gencies, including ambulance use, emergency depart-
ment visits and hospitalization, and life-threatening
events such as unconsciousness during asthma at-
tacks, attacks requiring respirator management, and
asthma attacks induced by an anti-inflammatory
agent (aspirin intolerant asthma, AIA). The subjects
were required to answer “yes” or “no” to the follow-
ing five questions: “Have you ever been hospitalized
due to asthma?” “Have you ever been taken by ambu-
lance or visited an emergency room due to an at-
tack?” “Have you ever used a respirator due to an
asthma attack?” “Have you ever been unconscious
due to an asthma attack?” and “Have you ever had an
attack induced by anti-inflammatory drugs including
painkillers, antipyretics, or cold medicines?” To evalu-
ate problems in asthma management and treatment
related to normal activity levels, the questionnaires
asked patients about their satisfaction in daily life.
The subjects answered by choosing 1 of 5 answers:
“very satisfied,” “fairly satisfied,” “mediocre,”
“slightly dissatisfied, “and “dissatisfied.”
In addition to the patients’ completing the question-
naire, their physicians were asked to supply details of
current treatment, primarily identifying control medi-
cation, the type of asthma (atopic or nonatopic) in ac-
cordance with the elevation of serum total IgE or de-
tection of specific IgE for allergens, and the severity
of asthma in accordance with the Japanese Society of
Allergology guideline for the diagnosis and manage-
ment of bronchial asthma. The definition of severity
of asthma is essentially the same as that used by the
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Table 1 Questionnaires administered to asthma patients in this study (the original was in Japanese.)
Age:　　　years　　　　Gender: male/female
Question 1
When were you first given a diagnosis of bronchial asthma?　　Year:　　　　Month:　　　　Day:　
Question 2
1) Choose your smoking status
(non-smoker, ex-smoker, curent smoker)
2) To ex-smokers, please answer the folowing:
At what age did you start smoking?  Your starting age:
At what age did you stop smoking?   Your stopping age:
How many cigaretes did you smoke per day?  Cigaretes/day (mean):
Is your smoking cessation related to your asthma?　 Yes or No:
3) To curent smokers, please answer the folowing:
At what age did you start smoking?   Your starting age:
How many cigaretes do you smoke per day?  Cigaretes/day (mean):
Question 3
1) Do you use a peak-flow meter?　(Yes, No)
2) What was the average value of your peak-flow meter during the last 2 weeks?
morning:　　　　　　　　　　　　night:　　　　　　　　　　　　
Question 4　Select one answer to each of the folowing questions:
1) How often did you have asthma atacks during the last 12 months?
(frequent atacks, seasonal atacks, few atacks)
2) How often did you have asthma atacks during the last 2 weeks?
(5 ― 7/week, 3 ― 4/week, 1 ― 2/week, absent)
3) How severe were your asthma atacks during the last 2 weeks?
(impossible to move, impossible to lie down, possible to lie down, strider, dyspnea on exertion)
4) Have you ever been hospitalized due to asthma?
(yes, no)
5) Have you ever been taken by ambulance or visited an emergency room due to an atack?
(yes, no)
6) Have you ever been placed on a respirator due to an asthma atack?
(yes, no)
7) Have you ever been unconscious due to an asthma atack?
(yes, no)
8) Have you ever had an atack induced by anti-inflammatory drugs including painkilers, antipyretics, or cold medicine?
9) Have you been absent from work or school due to an asthma atack?
(yes, no)
Question 5
How bad was your asthma during the last 2 weeks?
(very good, fairly good, mediocre, slightly bad, bad)
Question 6
Describe your symptoms during the last 2 weeks:
1) in the morning
(cough, sputum, chest tightness, stridor, dyspnea, no symptoms)
2) at night
(cough, sputum, chest tightness, stridor, dyspnea, no symptoms)
3) sleep disturbance
(sometimes cannot fal asleep due to dyspnea, cannot have a good sleep due to dyspnea, waking up in the night due to 
chest tightness, none)
Question 7
Do you feel satisfied with your daily life?
(very satisfied, fairly satisfied, mediocre, slightly dissatisfied, dissatisfied)
Question 8
Select one answer to each of the folowing questions if you are a woman.
1) Are you curently menstruating?
(yes, no)
2) Does your menstruation influence your asthma symptoms?
(always, sometimes, no)
Only answer the folowing questions if you answered ‘always’ or ‘sometimes’ in Question 8.2.
3) In what way does your menstruation influence your asthma symptoms?
(worsens symptoms, improves symptoms)
4) When are your asthma symptoms influenced?
(before menstruation, during menstruation, after menstruation)
Global Initiative for Asthma.
Among all female patients who were menstruating
during the survey period, patients who reported
asthma exacerbation related to menstruation were al-
located to the PMA group and those who did not
were allocated to the non-PMA group.
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Table 2 Patient background
PMAnon-PMA
38.2＋ /－9.7 36.8＋ /－9.5 age (mean＋ /－SD)
13.9＋ /－10.711.9＋ /－10.7duration (year: mean＋ /－SD)
87.5/12.5 (49/5)84.6/15.4 (351/64)type: % (N: atopic/nonatopic)
22.2/25.9/42.6 ＊ /9.3 ＊ (12/14/23/5)34.3/34.8/28.8/2.8 (137/139/115/11)severity: % (N: Step1/2/3/4)
74.5 ＊ /21.8/3.6 ＊ (41/12/2)57.1/24.3/18.2 (238/103/76)smoking status: % (N: Non/Ex/Cu)
21 (37.5)115 (36.6)number of PEF user (%)
＊ :p＜0.05 v.s. non-PMA, PMA: perimenstrual asthma, Non: non-smoker, Ex: ex-smoker, Cu: curent smoker, PEF: peak flow meter
Table 3 Drug/Medication
PMAnon-PMA
 47/8 (83.9) 358/64 (84.4) ICS use/non-use (%use)
30/26 (53.6)＊157/265 (37.0)LTRA use/non-use (%use)
 6/50 (10.7)＊12/410 (2.8)OCS use/non-use (%use)
9.3＋ /－5.55.9＋ /－3.6OCS dose (mg/day: calculated as PSL)
29/17 (51.8)＊＊＊136/286 (32.1)LABA use/non-use (%use)
15/41 (26.8) 79/343 (18.6)salmeterol use/non-use (%use)
39/17 (69.6)＊＊＊190/232 (44.8)OSRT use/non-use (%use)
＊ :p＜0.05, ＊＊＊ :p＜0.001 v.s. non-PMA, PMA: perimenstrual asthma, ICS: inhaled corticosteroid, LTRA: leukotriene receptor antago-
nist, OCS: oral corticosteroid, PSL: predonisolone, LABA: long acting beta2 agonist, OSRT: oral sustained-released theophyline
Table 4-a Incidence of asthma atacks, percentages of predicted peak flow values, asthma-related symptoms and sleep dis-
turbances during the 2 weeks prior to answering the questionnaire
PMAnon-PMA
26/29 ＊＊ (47.2/59.8) 100/273 (26.8/73.2)asthma atacks present/absent (%)
357.1＋ /－99.4385.5＋ /－70.1PEFV (morning, mean＋ /－SD)
364.7＋ /－92.2395.7＋ /－67.8PEFV (night, mean＋ /－SD)
36/20 ＊ (64.3/35.7)211/213 (49.8/50.2)ARS in morning: present/absent (%)
28/28 (50.0/50.0)173/251 (40.3/59.7)ARS in night: present/absent (%)
17/39 (30.4/69.6)91/333 (21.5/78.5)sleep disturbance: present/absent (%)
＊ :p＜0.05, ＊＊ :p＜0.01 v.s. non-PMA, PMA: perimenstrual asthma, PEFV: peak flow value, ARS: asthma-related symptoms
Table 4-b Asthma atacks and asthma-related work absences during the 1-year period prior to answering the questionnaire
PMAnon-PMA
25/12 ＊＊ /12 ＊＊ /7 (44.6/21.4/21.4/12.5)158/180/36/50 (37.3/42.5/8.5/11.8)seasonal/few/frequent/NA (%)
12/41 (22.6/77.4)73/326 (18.3/81.7)ARWA: present/absent (%)
＊＊ :p＜0.01 v.s. non-PMA, PMA: perimenstrual asthma, ARWA: asthma-related work or school absences
Table 5 Satifaction in daily life
very satisfied, fairly satisfied, mediocre, slightly dissatisfied, dissatisfied (%)
78/221/86/29/6 (18.4/52.1/20.3/6.8/1.4)non-PMA
7/26/14/8/0 (12.7/47.3/25.5/14.5/0.0)PMA
PMA: perimenstrual asthma
The results are expressed as arithmetic means
(±SD) for continuous variables. The differences be-
tween dichotomous variables were analyzed by chi-
square test. The Kruskal-Wallis test was used to test
for the equality of distributions of continuous vari-
ables. The pairwise year-to-year comparison was per-
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Table 6 Hospitalization, ambulance use or ED visits, atacks with unconsciousness, respirator management and AIA atacks
PMAnon-PMA
28/27 ＊ (50.9/49.1)153/260 (37.0/63.0)hospitalization: present/absent (%)
36/18 ＊＊＊ (67.9/32.1)174/242 (41.8/58.2)ambulance use or ED visits: present/absent (%)
 9/46 ＊＊＊ (16.4/83.6)15/392 (3.7/96.3)atacks with unconsciousness: present/absent (%)
 4/49 (7.5/92.5)20/382 (5.0/95.0)respirator management: present/absent (%)
14/41 ＊＊＊ (25.5/74.5)35/380 (8.4/91.6)AIA atacks: present/absent (%)
＊ :p＜0.05, ＊＊＊: p＜0.001 v.s. non-PMA, PMA: perimenstrual asthma, ED: emergency department, AIA: aspirin induced asthma
formed by chi-square test and Wilcoxon’s rank sum
test with Bonferroni’s correction for the significance
level. All statistical analyses were performed with the
statistical software BMDP 3S (BMDP, Los Angeles,
CA, USA) and Statxact (Cytel Software Co., Cam-
bridge, MA, USA).
RESULTS
PATIENT BACKGROUND
Of the female patients who were menstruating during
the study period, 56 were classified as being in the
PMA group and 424 were classified as being in the
non-PMA group. Of the PMA patients, 37 (66.1%) re-
ported that menstruation sometimes influenced their
asthmatic symptoms, and 19 (33.9%) reported that
menstruation always influenced their asthma. Asth-
matic symptoms worsened in 51 patients (91.1%) with
PMA; there were no reports of improved symptoms
during menstruation. Asthma symptoms were af-
fected in 30 patients (53.6%) before, in 9 patients
(16.1%) beforeduring and in 14 patients (25.0%) dur-
ing menstruation. The backgrounds of patients in the
PMA and non-PMA groups are summarized in Table
2. The proportion of patients with step 3 and 4 dis-
ease severity was significantly higher in the PMA
group than in the non-PMA group. The proportion of
non-smokers was also significantly higher in the
PMA group than in the non-PMA group. There were
no significant differences in age, disease duration,
type of asthma, or in the number of PEF users be-
tween the groups.
DRUGMEDICATION
In terms of medication (Table 3), there was a signifi-
cantly higher usage of leukotriene receptor antago-
nists (LTRA), oral corticosteroids (OCS), long-acting
beta2 agonists (LABA) and oral sustained-released
theophylline (OSRT) among patients in the PMA
group compared with the non-PMA group. A ten-
dency towards higher usage of salmeterol in the
PMA group was noted but was not significant.
ASTHMA CONTROL AND SYMPTOMS
There were no significant differences between the
two groups in asthma control and symptoms during
the 2 weeks prior to answering the survey, except
that there was a higher rate of asthma attacks among
patients in the PMA group compared with the non-
PMA group (Table 4-a). During the 1-year period
prior to answering the survey, the proportion of re-
spondents who reported ‘frequent’ asthma attacks
was significantly higher in the PMA group than in the
non-PMA group, despite no significant differences in
asthma-related work or school absences (Table 4-b).
SATISFACTION IN DAILY LIFE AND ASTHMA-
RELATED EMERGENCY EPISODES
There was no significant difference in satisfaction in
daily life between the two groups (Table 5). The re-
sults regarding asthma-related emergency episodes
are summarized in Table 6. Higher rates of hospitali-
zation, ambulance or emergency department visits
were reported by patients in the PMA group com-
pared with those in the non-PMA group. The rates of
asthma attacks with unconsciousness and AIA epi-
sodes were also significantly higher in the PMA
group than in the non-PMA group.
DISCUSSION
In this study, we reported on the characteristics of
PMA based on responses to a questionnaire survey.
The first problem when proposing a study of PMA is
defining what PMA is. In spite of many studies on
PMA, no standard definition of PMA has been estab-
lished. In many of these studies, exacerbation of asth-
matic symptoms in association with menstruation was
used as the definition of PMA,2,4,7-10,23,24 although de-
creases in forced expiratory flow (FEV1) or in PEF,
scoring of symptoms and frequency of rescue medi-
cation for attacks were sometimes used instead. Note
that the definition of PMA used in this report was ret-
rospective self-reports of exacerbation of asthma
symptoms based on responses to the questionnaire.
Regarding the rate of PMA, there was an interest-
ing discrepancy between previous studies and our re-
sults. In western countries, the rate of PMA in men-
struating female patients has been reported to be 30―
40%. However, the PMA rate found in this study was
only 11.3%. It is well known that some patients with
PMA cannot recognize exacerbations of their asth-
matic symptoms or decreases in respiratory func-
tion.4,10 Chandler et al. showed that only 5 patients
with PMA recognized the exacerbation of their asth-
matic symptoms by themselves, even though de-
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creases in FEV1 of more than 20% were associated
with menstruation in all 20 patients.12 This may be
the reason for the low rate of PMA found in our
study. In fact, a previous study in Europe, which simi-
larly used self-reports of exacerbated symptoms in re-
sponse to a questionnaire to define PMA, showed
only an 8.2% PMA rate,11 suggesting that the ob-
served differences in the incidence of PMA are not
due to race but to study design. However, both physi-
cians and female asthma patients should pay atten-
tion to the current lack of patient knowledge relating
to PMA because predictive factors of asthma exacer-
bation, such as menstruation, are, in practice, very
important in the management of female patients with
asthma.
Because our questionnaire survey only addressed
limited clinical features of asthma, it is impossible to
compare these results with the clinical characteristics
of PMA that were discussed previously, namely, the
associations with duration and cycle of menstruation,
use of contraceptives and PMA-specified symptoms.
However, there were some obvious clinical features
of PMA in this study. Regarding the severity of
asthma, including the frequency of asthma attacks
and symptoms (shown in Tables 2, 4), patients in the
PMA group suffered more severe asthma than pa-
tients in the non-PMA group, similar to results from
previous studies.8,9,16,24-26 Therefore, more aggressive
patient management, including increased oral corti-
costeroid use, was used with patients in the PMA
group than in the non-PMA group (Table 3). The
rates of emergency episodes in the PMA group, in-
cluding hospitalization, ambulance or emergency de-
partment visits, were higher than in the non-PMA
group. These were also similar to those reported in
previous studies.27-31
Among the clinical features of PMA outlined in this
report, it is very interesting to note that there was a
significantly greater proportion of AIA (25.5%) among
patients in the PMA group compared with the non-
PMA group (8.4%). This may indicate a significant as-
sociation between PMA and AIA. Moreover, the char-
acteristics of AIA reported previously are very similar
to those of PMA.19,32,33 LTRA have been reported to
be effective in asthma control in both PMA25 and
AIA.34,35 The use of nonsteroidal anti-inflammatory
drugs in PMA might not cause this relation, because
Forbes et al. reported that there was no association
between the use of nonsteroidal anti-inflammatory
drugs and PMA.11 These results may indicate that a
shared dysfunction of leukotriene and prostaglandin
metabolism may be involved in PMA and AIA. Al-
though there is no established cause of PMA, this
similarity may contribute to the elucidation of the
mechanism of PMA and may present a new strategy
not only for PMA but also for AIA.
In summary, using a questionnaire survey con-
ducted in Japan, we compared the clinical features of
PMA with those reported previously. The lower rate
of PMA found in this study is likely due to the study
method used, namely self-reports of PMA. Both phy-
sicians and their female asthma patients should pay
attention to the current lack of patient knowledge re-
lating to PMA. An interesting observation in this
study was that there was a significant increase in the
incidence of AIA among patients in the PMA group
compared with the non-PMA group, indicating that
the clinical similarity between PMA and AIA may pro-
vide a new insight into the mechanism of PMA.
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